# Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine

> **NCT02200991** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 136 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** LIXISENATIDE AVE0010
- **DRUG:** Sitagliptin
- **DRUG:** Insulin glargine HOE901

## Key facts

- **NCT ID:** NCT02200991
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2016-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02200991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02200991, "Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02200991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*